Publications by authors named "Sarajane Ross"

Claim this Profile
B
Balancing Efficacy and Safety of an Anti-DLL4 Antibody through Pharmacokinetic Modulation.
Jessica A Couch, Gu Zhang, Joseph C Beyer, Christina L Zuch de Zafra, Priyanka Gupta, Sarajane Ross

Clin Cancer Res· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dose dependent pharmacokinetics, tissue distribution, and anti-tumor efficacy of a humanized monoclonal antibody against DLL4 in mice.
Amrita V Kamath, Victor Yip, Priyanka Gupta, C Andrew Boswell, Daniela Bumbaca, Sarajane Ross

MAbs· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An antimesothelin-monomethyl auristatin e conjugate with potent antitumor activity in ovarian, pancreatic, and mesothelioma models.
Suzie J Scales, Nidhi Gupta, Glenn Pacheco, Ron Firestein, Dorothy M French, Sarajane Ross

Mol Cancer Ther· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mapping in vivo tumor oxygenation within viable tumor by 19F-MRI and multispectral analysis.
Yunzhou Shi, Jason Oeh, Jeffrey Eastham-Anderson, Sharon Yee, David Finkle, Jed Ross, Sarajane Ross

Neoplasia· November 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Blocking NRG1 and other ligand-mediated Her4 signaling enhances the magnitude and duration of the chemotherapeutic response of non-small cell lung cancer.
Ganapati V Hegde, Cecile C de la Cruz, Cecilia Chiu, Navneet Alag, Gabriele Schaefer, Sarajane Ross

Sci Transl Med· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of anti-VEGF on pharmacokinetics, biodistribution, and tumor penetration of trastuzumab in a preclinical breast cancer model.
Cinthia V Pastuskovas, Eduardo E Mundo, Simon P Williams, Tapan K Nayak, Jason Ho, Sarajane Ross

Mol Cancer Ther· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Erratum to: Ungersma SE, Pacheco G, Ho C, Yee SF, Ross J, van Bruggen N, Peale FV Jr, Ross S, Carano RA. Vessel imaging with viable tumor analysis for quantification of tumor angiogenesis. Magn Reson Med 2010;63:1637–1647.
Sharon E Ungersma, Glenn Pacheco, Calvin Ho, Sharon Fong Yee, Jed Ross, Sarajane Ross

Magn Reson Med· March 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An Fcγ receptor-dependent mechanism drives antibody-mediated target-receptor signaling in cancer cells.
Nicholas S Wilson, Becky Yang, Annie Yang, Stefanie Loeser, Scot Marsters, Sarajane Ross

Cancer Cell· January 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of immune complex formation on the distribution of a novel antibody to the ovarian tumor antigen CA125.
Cinthia V Pastuskovas, William Mallet, Suzanna Clark, Margaret Kenrick, Mohammed Majidy, Sarajane Ross

Drug Metab Dispos· December 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vessel imaging with viable tumor analysis for quantification of tumor angiogenesis.
Sharon E Ungersma, Glenn Pacheco, Calvin Ho, Sharon Fong Yee, Jed Ross, Sarajane Ross

Magn Reson Med· June 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quantifying antivascular effects of monoclonal antibodies to vascular endothelial growth factor: insights from imaging.
James P B O'Connor, Richard A D Carano, Andrew R Clamp, Jed Ross, Calvin C K Ho, Sarajane Ross

Clin Cancer Res· November 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical evaluation of carcinoembryonic cell adhesion molecule (CEACAM) 6 as potential therapy target for pancreatic adenocarcinoma.
Laura A Strickland, Jed Ross, Simon Williams, Sarajane Ross, Maria Romero

J Pathol· July 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice.
Jing Qing, Xiangnan Du, Yongmei Chen, Pamela Chan, Hao Li, Sarajane Ross

J Clin Invest· May 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antibody-drug conjugates for the treatment of non-Hodgkin's lymphoma: target and linker-drug selection.
Andrew G Polson, Jill Calemine-Fenaux, Pamela Chan, Wesley Chang, Erin Christensen, Sarajane Ross

Cancer Res· March 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Variants of the antibody herceptin that interact with HER2 and VEGF at the antigen binding site.
Jenny Bostrom, Shang-Fan Yu, David Kan, Brent A Appleton, Chingwei V Lee, Sarajane Ross

Science· March 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antixenograft tumor activity of a humanized anti-insulin-like growth factor-I receptor monoclonal antibody is associated with decreased AKT activation and glucose uptake.
Yonglei Shang, Yifan Mao, Jennifer Batson, Suzie J Scales, Gail Phillips, Sarajane Ross

Mol Cancer Ther· September 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index.
Jagath R Junutula, Helga Raab, Suzanna Clark, Sunil Bhakta, Douglas D Leipold, Sarajane Ross

Nat Biotechnol· August 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quantification of viable tumor microvascular characteristics by multispectral analysis.
Leanne R Berry, Kai H Barck, Mary Ann Go, Jed Ross, Xiumin Wu, Sarajane Ross

Magn Reson Med· July 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MetMAb, the one-armed 5D5 anti-c-Met antibody, inhibits orthotopic pancreatic tumor growth and improves survival.
Hongkui Jin, Renhui Yang, Zhong Zheng, Mally Romero, Jed Ross, Sarajane Ross

Cancer Res· June 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cooperation of the proapoptotic receptor agonist rhApo2L/TRAIL with the CD20 antibody rituximab against non-Hodgkin lymphoma xenografts.
Dylan Daniel, Becky Yang, David A Lawrence, Klara Totpal, Inessa Balter, Sarajane Ross

Blood· December 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antibody-drug conjugates targeted to CD79 for the treatment of non-Hodgkin lymphoma.
Andrew G Polson, Shang-Fan Yu, Kristi Elkins, Bing Zheng, Suzanna Clark, Sarajane Ross

Blood· July 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Armed antibodies targeting the mucin repeats of the ovarian cancer antigen, MUC16, are highly efficacious in animal tumor models.
Youjun Chen, Suzanna Clark, Terence Wong, Yongmei Chen, Yvonne Chen, Sarajane Ross

Cancer Res· May 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Imaging tumors with an albumin-binding Fab, a novel tumor-targeting agent.
Mark S Dennis, Hongkui Jin, Debra Dugger, Renhui Yang, Leanne McFarland, Sarajane Ross

Cancer Res· January 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Blocking neuropilin-1 function has an additive effect with anti-VEGF to inhibit tumor growth.
Qi Pan, Yvan Chanthery, Wei-Ching Liang, Scott Stawicki, Judy Mak, Sarajane Ross

Cancer Cell· January 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
K
Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib.
Kendall D Carey, Andrew J Garton, Maria S Romero, Jennifer Kahler, Stuart Thomson, Sarajane Ross

Cancer Res· August 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis